All Activity

A coalition of Texas hemp industry leaders and advocacy organizations are suing state officials over recently enacted rules restricting access to hemp-derived products such as smokable THCA flower. The lawsuit, brought by the Texas Hemp Business Council (THBC), Hemp Industry & Farmers of America (HIFA) and several businesses, alleges that the Department of State Health Services (DSHS) and the Health and Human Services Commission (HHSC) illegally bypassed lawmakers to restrict the sale and manufacture of consumable hemp products. The dispute centers on how hemp is defined. Under state law as approved by the legislature and governor in 2019, the suit says, cannabis products are legal if they contain a delta-9 THC concentration of not more than 0.3 percent. But regulators at DSHS and HHSC recently adopted a “total delta-9 THC” limit using a post-decarboxylation formula that includes tetrahydrocannabinolic acid (THCA) in the calculation. “These Texas officials and state agencies are clearly attempting to create new law in direct contradiction to what the Texas legislature intended,” David Sergi, a lawyer leading the case, said in a press release. “The Texas hemp business community is not challenging rules related to age verification or consumer protections. They wholeheartedly support those regulations, as they fall within the agency’s authority,” he said. “We are seeking to halt rules that would effectively end the in-state production of hemp and the sale of hemp products—items the Legislature chose not to ban during recent legislative and special sessions.” THBC has filed a lawsuit to challenge rules that threaten compliant businesses and overstep legal authority. These rules don’t just tighten regulation–they rewrite the law. This is about more than hemp. It’s about accountability, fair regulation & protecting Texas business. pic.twitter.com/yxP9jNhTXO — Texas Hemp Business Council (@TexasHempBiz) April 8, 2026 Texas lawmakers did pass legislation to severely restrict hemp products in the 2025 legislation, but it was vetoed by Gov. Greg Abbott (R) and not enacted into law. The hemp industry lawsuit, which also lists Attorney General Ken Paxton (R) as a defendant, additionally challenges large increases in business licensing fees that regulators adopted. Under the new rules, the cost for a manufacturer license increased from $250 to $10,000 per facility, while the fee for retailer registration jumped from $150 to $5,000 per location. “These measures do not implement the Legislature’s policy choices; they replace them,” the complaint says. “And they do so against the backdrop of a constitutional lawmaking process that ran its full course—from legislative passage of Senate Bill 3 through gubernatorial veto, through two failed special sessions—and produced an unambiguous result: no new law. Texas law does not permit agencies to override that result through rulemaking.” “Texas has long promoted itself as a national leader in economic growth and regulatory stability. It is a state committed to fostering innovation, supporting lawful enterprise, and maintaining a predictable legal environment in which businesses can operate and invest,” it says. “Consistent with that approach, Texas has chosen to permit and regulate the manufacture, distribution, and sale of consumable hemp products (“CHPs”) through a comprehensive statutory framework enacted by the Legislature in 2019. “Plaintiffs support that framework and the State’s interest in ensuring that CHPs are produced and sold safely, responsibly, and in compliance with law,” the suit says. The plaintiffs are asking the District Court of Travis County to grant an immediate temporary restraining order to block enforcement of the news rules, as well as temporary and permanent injunctive relief. Separately, Texas officials recently conditionally approved more new medical marijuana business licenses as part of a law that’s being implemented to significantly expand the state’s cannabis program. Last month, Texas voters approved a marijuana legalization question that appeared on the state’s Democratic primary ballot. A statewide poll released in February found that Texas voters don’t like how state leaders and lawmakers have handled marijuana and THC policy issues. In the survey, a plurality of voters (40 percent) said they disapprove of how their elected officials have approached the issue, according to the survey. Just 29 percent said they approve of how cannabis issues have been handled, while 31 percent said they didn’t have an opinion one way or another. A separate poll released last year found that a plurality of Texas voters want the state’s marijuana laws to be made “less strict.” And among the legislative items lawmakers considered during recent special sessions, voters say a proposal to address hemp regulations was among the least important. Meanwhile, the lieutenant governor and House speaker announced recently that the state will proceed with its own ibogaine research program after no drug companies submitted proposals meeting requirements and standards to receive state funds to begin clinical trials with the psychedelic under a recently enacted law. Read the new Texas hemp lawsuit below: The post Texas Hemp Businesses Sue State Officials Over New Rules Banning Products Like Smokable THCA Flower appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for the blog post buddy! Keep them coming... 신용카드 현금화

I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. 신용카드 현금화

There’s been a new breakthrough in the development of a marijuana breathalyzer, with a study partly funded by the Justice Department showing a potential pathway for a “portable, low cost” device that looks like an inhaler for asthma, built with 3-D printed material that can detect delta-9 THC without secondary lab analysis. The study, led by Emanuele Alves at Virginia Commonwealth University (VCU), detailed the results of experiments meant to address the current lack of a roadside impairment test for THC similar to those utilized by law enforcement for people suspected of driving under the influence of alcohol. With more states legalizing cannabis, there’s particular “need for rapid, reliable and low-cost roadside tools,” it says. By using 3-D printed cartridges with a “Fast Blue” dye and gelatin system, the colorimetric experiments established “foundational data” that the device can be used to detect delta-9 THC, CBD and CBN “across multiple matrix systems.” The tool was able to detect 10-100 nanograms of the cannabinoids, which could be differentiated using color-space modeling. Specifically, the tests revealed “two primary clusters,” with evidence that delta-9 THC and CBN analytes can be distinguished from CBD analytes based on color hue. “Overall, this project established foundational data supporting the feasibility of a portable, low-cost, colorimetric tool for detecting cannabinoids using 3D-printed cartridges and readily accessible reagents,” the study says. “While additional validation and field-oriented development are needed, these findings provide a proof-of-concept framework for future roadside or point-of-collection testing technologies.” The Justice Department provided funding for the study and posted the results on the Office of Justice Programs’s National Criminal Justice Reference Service website last month, but the author’s findings “do not necessarily reflect the official position or policies” of the agency, it says. “The development of a breathalyzer for the early detection of marijuana’s recent use is an important matter considering the current legal status of marijuana-based products around the country,” VCU’s Alves said. “To achieve this goal, our initial approach was to develop a portable cartridge that would be able to react with cannabinoids selectively to detect THC use, but not CBD.” “Most THC breathalyzers in the market are merely collection devices that will need further laboratory analysis,” he continued. “Considering the working system of an alcohol breathalyzer, using a redox reaction would be risky for the THC approach as it would not be selective for the specific cannabinoids and it would give a positive result to any molecule capable of oxidizing the reagent.” Because of the “excellent results” of the experiment in the “establishment of the foundational chemical profile needed for the development of a THC breathalyzer,” the study says, a patent application has been filed with the U.S. Patent and Trademark Office (USPTO), with a proposed design for a future prototype. There are three main components to the device, which the author said looks similar to inhalers for people with asthma. There’s a mouthpiece for exhaled air to be collected, a cartridge fixed to the end of the instrument where delta-9 THC particles “collide and react” and a detection system where the colorimetric reaction occurs and forms a dark red color if it’s positive for the intoxicating cannabinoid. “The consequences and legal penalties for driving under the influence (DUI) of alcohol are well publicized,” the study concludes. “However, what the general population ignores is the illegality of DUI of marijuana, in combination or not with other drugs.” “With the legalization of cannabis consumption in many parts of the USA, this lack of information from the general population has increased the risk of accidents and deaths caused by drivers intoxicated with marijuana. Due to the difficult and costly current methods available for the detection of marijuana in samples, it is vital to create and improve technologies for its detection in a fast, reliable, and in situ method for public safety and awareness.” “The outcome of this project is the fundamental chemical foundation and the initial prototype for the development of a ∆9-THC breathalyzer,” the author said. “The device developed in this project is a portable tool to increase safety on the roads and for ∆9-THC use monitoring.” Federal agencies outside of DOJ have also recognized the need for the THC detection technology. For example, last year the National Institute of Standards and Technology (NIST) under the U.S. Department of Commerce planned a workshop aimed at facilitating “an open and candid discussion” about the development and implementation of device to test a person’s breath for marijuana impairment. In 2023, a federally funded report by researchers at NIST and the University of Colorado Boulder concluded that evidence does “not support the idea that detecting THC in breath as a single measurement could reliably indicate recent cannabis use.” A DOJ researcher in 2024, meanwhile, cast doubt on whether a person’s THC levels are even a reliable indicator of impairment, saying states may need to “get away from that idea.” Scott questioned the efficacy of setting “per se” THC limits for driving that some states have enacted, making it so a person can be charged with driving while impaired based on the concentration of cannabis components in their system. Ultimately, there may not be a way to assess impairment from THC like we do for alcohol, she said. One complication is that “if you have chronic users versus infrequent users, they have very different concentrations correlated to different effects,” Scott said. “So the same effect level, if you will, will be correlated with a very different concentration of THC in the blood of a chronic user versus an infrequent user.” That issue was also examined in a federally funded study in 2024 that identified two different methods of more accurately testing for recent THC use that accounts for the fact that metabolites of the cannabinoid can stay present in a person’s system for weeks or months after consumption. Also that year, researchers behind a federally funded study said they’d developed new procedures to enhance the selectivity of a popular forensic testing method, allowing better detection of delta-9 THC and its metabolites in blood. A 2023 congressional report for a Transportation, Housing and Urban Development, and Related Agencies (THUD) bill said that the House Appropriations Committee “continues to support the development of an objective standard to measure marijuana impairment and a related field sobriety test to ensure highway safety.” A study published in 2019 concluded that those who drive at the legal THC limit—which is typically between two to five nanograms of THC per milliliter of blood—were not statistically more likely to be involved in an accident compared to people who haven’t used marijuana. Separately, the Congressional Research Service (CRS) in 2019 determined that while “marijuana consumption can affect a person’s response times and motor performance … studies of the impact of marijuana consumption on a driver’s risk of being involved in a crash have produced conflicting results, with some studies finding little or no increased risk of a crash from marijuana usage.” Another study from 2022 found that smoking CBD-rich marijuana had “no significant impact” on driving ability, despite the fact that all study participants exceeded the per se limit for THC in their blood. In a separate report last year, the U.S. National Highway Traffic Safety Administration (NHTSA) said there’s “relatively little research” backing the idea that THC concentration in the blood can be used to determine impairment, again calling into question laws in several states that set “per se” limits for cannabinoid metabolites. “Several states have determined legal per se definitions of cannabis impairment, but relatively little research supports their relationship to crash risk,” that report said. “Unlike the research consensus that establishes a clear correlation between [blood alcohol content] and crash risk, drug concentration in blood does not correlate to driving impairment.” Congressional lawmakers at hearings last year also heard from representatives of the trucking industry, who called for wider use of hair-follicle testing in the industry. The chair of the National Transportation Safety Board (NTSB), meanwhile, recommended better education for drivers. “At time when conversations lean towards the potential reclassification of marijuana from a Schedule I to Schedule III narcotic, demonstrating that this problem is likely to only grow,” said a representative for Truckload Carriers Association, “our industry in its entirety is unable to properly employ the proper test to identify habitual users and enter them into a substance abuse program and begin the return-of-duty procedures.” The transportation industry also advised Congress in January that if marijuana is federally rescheduled, businesses want assurances that they won’t have to forgo zero-tolerance drug policies for drivers—while stressing that a key problem for the sector is a lack of technology to detect impaired driving. The issue of marijuana-impaired driving also arose at another recent congressional hearing, with a representative of the Governors Highway Safety Association emphasizing the importance of roadside drug testing as a tool to help combat deadly car crashes. Last year, meanwhile, the U.S. Supreme Court ruled in favor of a trucker who sued a cannabis company after he was fired over a positive THC test that he said was caused by consuming a hemp-derived CBD product. Separately, a Substance Abuse and Mental Health Services Administration (SAMHSA) official recently downplayed criticism from the CEO of a drug-testing company that more widespread use of saliva-based drug testing “means truckers who use cannabis will be able to do so with near impunity, as long as they avoid a drug test for a couple of days.” “When a donor receives a request for collection, the donor will not know if the test will be an oral fluid or urine collection until they arrive at the collection facility for a federal agency,” the unidentified SAMHSA official said in response. Not knowing whether to expect a saliva or urine test, in other words, would prevent drivers simply stopping marijuana use a few days before a saliva-based test. The post Federally Funded Study Reveals Marijuana Breathalyzer Breakthrough With 3-D Printed Roadside Tool Able To Detect THC appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Pretty good post. I just stumbled upon your blog and wanted to say that I have really enjoyed reading your blog posts. Any way I'll be subscribing to your feed and I hope you post again soon. Big thanks for the useful info. 카드현금화

Maryland lawmakers have sent the governor a bill to extend a psychedelics task force through the end of 2027, charging it with developing updated recommendations on expanding therapeutic access to the novel substances and potentially creating a regulatory framework for broader legalization. The House of Delegates on Thursday voted 109-24 to approve a Senate-passed version of the legislation from Sen. Brian Feldman (D). The bill next heads to the desk of Gov. Wes Moore (D) as companion House psychedelics legislation from Del. Pam Guzzone (D) awaits final action in the Senate. Both chambers’ proposals are aimed at building upon a current law that created the Maryland Task Force on Responsible Use of Natural Psychedelic Substances. The Senate version of the bill was amended in that chamber to add a representative of a historically black college or university (HBCU) to the task force. Guzzone recently said that she wants senators to amend her bill to also add the HBCU representative so that both versions are identical, which the Senate Finance Committee did on Tuesday. The psychedelics panel released an initial final report to state lawmakers last year, with recommendations for the phased implementation of a wide range of reforms to provide legal therapeutic access to substances such as psilocybin. Members of the task force have already advised that it was ultimately recommending a “multi-pathway framework for safe, broad, and equitable access to natural psychedelic substances, with an initial focus on psilocybin.” The psychedelics task force was formed following the governor’s signing of a pair of bills into law in 2024. The 17-person body, overseen by the Maryland Cannabis Administration (MCA), was charged with studying how to ensure “broad, equitable and affordable access to psychedelic substances” in the state. SB 336 and HB 427 would continue that work, maintaining the panel through December 31, 2027. In the interim, the task force would be required to submit an updated report to legislators with additional findings and recommendations by October 31 of this year. Beyond the extended timeline for the task force to study and develop the new report, the current law would not change under the legislation. The multi-step regulatory framework that members recommended last year “involves phased implementation of complementary elements from medical/therapeutic use and supervised adult use, to deprioritization, and to commercial sales,” the earlier report said. “This model broadly and inclusively serves the needs of Maryland’s diverse population while enabling unified safety standards, accountability, and viable economic pathways for small businesses.” The first phase of the plan would be to create an advisory board to establish safety parameters, data monitoring, practice guidelines, licensing protections, public education campaigns, training for facilitators, law enforcement and testing facilities, as well as “immediate restorative justice measures,” the report states. Under phase two, the state would implement “deprioritization measures” to mitigate the harms of criminalization, provide for supervised medical and adult-use consumption facilities, allow personal cultivation for “permitted individuals” and promote research processes. Finally, phase three would be contingent on the “demonstrated safety outcomes and provider confidence” based on the prior steps. Should those factors be satisfied, the last phase would lead to a commercial sales program for adults “who maintain an active license to use natural psychedelic substances,” coupled with an evaluation of the state’s “readiness for expanding to additional natural psychedelic substances.” “Safety and oversight measures ensure responsible and gradual expansion of access while maintaining capacity to identify and respond to emerging issues swiftly,” the report said. “This approach plans for long-term learning and improvement: starting small, utilizing built-in evaluation and accountability mechanisms from the outset, gathering real-world data, and committing to an iterative approach to policymaking.” Notably, the task force said it did not support “delaying state action pending future federal [Food and Drug Administration] approval.” “The Task Force recognizes that implementing such a comprehensive framework requires careful sequencing and coordination, with particular attention to scope of practice issues that may significantly affect the viability and safety of different pathways. However, the order of implementation must carefully consider professional regulatory frameworks and safety concerns raised by medical organizations and health care providers. The Task Force’s recommendation for simultaneous implementation of multiple pathways does not mean that all components must activate on the exact same day, but rather that Maryland should avoid the sequential approach seen in other jurisdictions where implementing one pathway causes others to ‘languish,’and/or bolster black and gray markets.” Rather, the task force said, the multi-phase approach to psychedelics reform “establishes foundational systems that support all pathways equally, followed by a coordinated launch of medical, supervised adult use, and deprioritization pathways, with commercial sales following once product safety systems are operational.” Members also said that the model envisioned could be used by other states to develop their own laws that “adapt to their own circumstances and values.”At this point, the task force is only looking at psilocybin, mescaline and DMT. While the legislature empowered members to investigate potential regulations for other psychedelic substances, they decided to take a more conservative approach in their initial work. As originally introduced, the House version of the task force legislation contained more prescriptive requirements to explore and issue recommendations on aspects of psychedelics policy such as “systems to support statewide online sales of natural psychedelic substances with home delivery” and “testing and packaging requirements for products containing natural psychedelic substances with clear and accurate labeling of potency.” That language was ultimately removed, however. The task force legislation advanced about two years after a different law took effect creating a state fund to provide “cost-free” access to psychedelics like psilocybin, MDMA and ketamine for military veterans suffering from PTSD and traumatic brain injury. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile Maryland lawmakers are also advancing legislation to protect firefighters and rescue workers from being penalized over their lawful use of medical marijuana off the job after hearing testimony on the unique need to give emergency service professionals the option to use cannabis as an alternative treatment for health conditions that commonly afflict the first responder community. Legislators are also considered a bill to protect the gun rights of medical marijuana patients in the state. Members of the House Judiciary Committee discussed the legislation from Del. Robin Grammer (R), who has sponsored multiple versions of the cannabis and gun rights measure over recent sessions, but they have not yet advanced to enactment. Image courtesy of CostaPPR. The post Maryland Bill To Extend Psychedelics Task Force Through 2027 Heads To Governor’s Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Wow, this PITCH IT! series sounds like an incredible opportunity to enhance our public speaking skills and find our voices! I love how it focuses on both crafting a pitch and building confidence through the Ten Breaths Away method. It reminds me of the quordle concept, where we also learn to express ourselves clearly and creatively.

Choosing the right agency makes a big difference when you want a reliable service. Our Hotel JW Marriott Escorts Service is organized with full privacy and quick support. We focus on giving clients a smooth and well-managed experience without any delay.

DEA: marijuana rescheduling appeal still “pending”; GOP congressman: let states legalize; MO gov on hemp THC ban; ID medical cannabis resolution Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Drug Enforcement Administration said in a new filing that the marijuana rescheduling appeal process is still on hold and “remains pending” despite President Donald Trump directing the attorney general to complete the reform “in the most expeditious manner” more than three months ago. “No briefing schedule has been set.” A former Drug Enforcement Administration senior advisor coauthored a new analysis concluding that federal marijuana laws are “neither coherent nor evidence based” and do “immense damage”—arguing that a different approach needs to be developed with a new “managed market access schedule” for drugs like cannabis and psilocybin that can apply “capitalism controls” rather than criminalization. Rep. Thomas Massie (R-KY) said states should be able to legalize cannabis without federal interference—even though he personally prefers “medical margaritas” to recreational marijuana. Pennsylvania Gov. Josh Shapiro (D) is stepping up pressure on lawmakers to legalize marijuana, saying that the reform can generate revenue to “make bigger investments in our kids, public safety, and our economy.” “Stop with the excuses. Let’s get this done.” Missouri Gov. Mike Kehoe (R) said restricting the sale of intoxicating hemp-derived THC products is “definitely something we need to get done” in line with a bill that lawmakers recently passed and sent to his desk. The Idaho House of Representatives joined the Senate in passing a resolution urging voters not to sign petitions to put a medical cannabis initiative on the November ballot—claiming that legalization causes crime, health and safety problems. An Ohio judge issued a temporary restraining order blocking enforcement of new hemp product restrictions, saying the policy immunizes the “in-state marijuana industry…from out-of-state competition with respect to federally legal hemp products otherwise sold in interstate commerce.” / FEDERAL The White House Office of National Drug Control Policy hosted an awards ceremony recognizing “law enforcement’s role in fighting against drug trafficking.” The House bill to designate psychedelic therapy centers of excellence got one new cosponsor for a total of 25. / STATES Oklahoma Republican gubernatorial candidates discussed their concerns with medical cannabis during a debate. Florida’s agriculture commissioner tweeted, “We remain undefeated in court against the hemp industry’s challenges to Florida’s laws protecting children from high-potency THC hemp products.” The Massachusetts Senate Ways and Means Committee released budget legislation proposing to spend $1 million on a public education campaign about the risks of marijuana. The Illinois Medical Cannabis Advisory Board voted to recommend adding sickle cell disease as a medical marijuana qualifying condition. Vermont regulators sent guidance about cannabis rules ahead of 4/20. California regulators posted an update about transitioning provisional cannabis licenses to annual licensure. Montana regulators sent a newsletter with various cannabis updates. / LOCAL The Minneapolis, Minnesota City Council is considering a proposal to decriminalize drug paraphernalia. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / SCIENCE & HEALTH A study in Germany “did not indicate increased cannabis consumption after the legalization.” A study found that cannabis seed “inclusion altered lipid metabolism and improved the fatty acid profile of broiler meat without marked adverse effects on growth performance, confirming its potential as a functional feed ingredient in poultry production.” / BUSINESS Vireo Growth Inc. is partnering with Ace Venture of NY, LLC to establish what it says is expected to become New York’s first scaled social equity operator emerging from the state’s first minority-owned vertically integrated medical cannabis license. / CULTURE Jimmy Kimmel is executive producing a new Hulu cannabis-focused docuseries. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Pennsylvania governor steps up cannabis legalization push (Newsletter: April 8, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

We specialise in the supply of storage products, including installation, relocation, and trade-ins. Having over 40 full-time staff plus qualified contractors operating from our three sites in Western Australia and South Australia, our operation areas cover over 15000m2 including management, sales, manufacturing, occupational health and safety (OHS) regulation, importing, fabrication, consulting, designing, human resources, administration, accounts, warehousing, inspectors and labour roles.

I am extremely delighted in for this web journal. Its a useful subject. It help me all that much to take care of a few issues. Its chance are so awesome and working style so rapid. visitor chair

Positive site, where did u come up with the information on this posting?I have read a few of the articles on your website now, and I really like your style. Thanks a million and please keep up the effective work. togel online

Pennsylvania’s governor is increasing pressure on lawmakers to send him a bill to legalize marijuana in the state, saying that doing so would generate new revenue that could be invested in key programs. “While some in Harrisburg claim we can’t afford to make bigger investments in our kids, public safety, and our economy, know this: If we legalized and regulated adult-use cannabis, we’d bring in $1.3 BILLION in revenue for our Commonwealth over the first five years,” Gov. Josh Shapiro (D) said in a social media post on Tuesday. “Those are dollars that can be invested back into our people and our communities,” he said. “Stop with the excuses. Let’s get this done.” Earlier this year, the governor again included marijuana legalization in his budget request to lawmakers, but so far the legislature has not enacted the reform. The Democratic-House of Representatives last year passed a bill to legalize marijuana and put sales in state-owned dispensaries, but the Republican Senate majority has criticized that plan while also not advancing a cannabis legalization model of its own. While some in Harrisburg claim we can’t afford to make bigger investments in our kids, public safety, and our economy, know this: If we legalized and regulated adult-use cannabis, we’d bring in $1.3 BILLION in revenue for our Commonwealth over the first five years. Those are… — Governor Josh Shapiro (@GovernorShapiro) April 7, 2026 The state’s Independent Fiscal Office (IFO) reported in February that legalizing cannabis in Pennsylvania would generate nearly half a billion dollars in annual revenue by 2028, an estimate that is a significantly larger cash windfall compared to projections from Shapiro’s own office. With a proposed 20 percent wholesale cannabis excise tax, 6 percent state sales tax for retail and licensing fees, IFO said the governor’s legalization plan would generate $140 million in tax revenue in the first year of implementation from 2027-2028 and increase to $432 million by 2030-2031. That’s a much higher revenue estimate than what the governor’s office put forward in the latest executive budget. According to his office’s analysis, legalization would generate about $36.9 million in tax dollars in its first year from a 20 percent wholesale tax on marijuana—rising gradually to $223.8 million by 2030-2031. Meanwhile, a recent Quinnipiac University Poll found that a majority of Pennsylvania voters say they’re ready for the state to legalize adult-use marijuana. In February, a coalition of drug policy and civil liberties organizations urged Shapiro to play a leadership role in convening legislative leaders to get the job done on cannabis legalization this session. Last month, the Senate Law and Justice Committee amended and approved a bill to create a Cannabis Control Board (CCB) to oversee the state’s medical marijuana program and intoxicating hemp products and that could eventually regulate adult-use cannabis if it is legalized in the state. The post Pennsylvania Governor Says Legalizing Marijuana Will Raise Revenue To Support Kids And Public Safety Programs appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Idaho House of Representatives has joined the Senate in approving a resolution urging voters to “reject” an effort to place an initiative to legalize medical marijuana on the state’s November ballot. The measure, sponsored by the Senate State Affairs Committee, claims that cannabis legalization in other states has led to a host of harms, including “increased cartel activity, development of black market marijuana production, human trafficking, and increased crime rates” as well as “increased rates of serious health issues,” environmental harms and “safety concerns on job sites.” After passing the Senate in a voice vote earlier last week, SCR 127 cleared the House on Wednesday in a 58-9 vote. It argues that the marijuana initiative would not only increase costs to the state but that its list of approved medical conditions is “so broad that almost anyone could qualify.” “The Idaho Medical Cannabis Act lacks safeguards to such an extent that it would effectively legalize widespread recreational use of marijuana,” the resolution claims. “The legalization of marijuana would have devastating impacts on Idaho children and their families… The Legislature urges the citizens of Idaho to reject any effort to bring the Idaho Medical Cannabis Act to the ballot.” A statement of purpose filed with the legislation says it “addresses the devastating impact that legalizing marijuana has had on other states” and “identifies the significant problems” with the ballot initiative. The Natural Medicine Alliance of Idaho (NMAI), which is leading the effort to place the legalization measure before voters this November, has pushed back against the resolution. “Idahoans deserve to vote on this issue, and we are confident we will be able to get it in front of them this November to do just that,” Amanda Watson, a spokesperson for the group, said in a press release last month when the resolution was filed. “There are thousands of people across Idaho with stories like Dr. Tunney’s and they deserve dignified care and the option to choose an alternative to opioids. NMAI has operating field offices in every corner of the state and we are actively recruiting more team members in Coeur d’Alene, Meridian, Boise, Twin Falls, Pocatello and Idaho Falls. We are not taking our foot off the gas until the final bell rings.” Contrary to the claims made about marijuana reform in the legislative resolution, advocates often point to data showing that legalizing and regulating cannabis diminishes the size of the illegal market and has not led to increases in youth use. Rep. Stephanie Mickelsen (R) said in a House State Affairs Committee hearing ahead of the floor vote that “I have traveled not only this country but across the globe, and I’m here to tell you everywhere that they have legalized marijuana, you see much more homelessness, you see people that are just completely out of it, and it is not something I want to see in Idaho.” Rep. Jaron Crane (R) compared places with legal marijuana access to Idaho’s biggest city. “It feels different walking in downtown Portland and Seattle than it does walking in Boise,” he said, KIVI-TV reported. “The cost will definitely always be higher than the benefit of projected tax revenue.” NMAI recently released an analysis showing that Idaho could see more than $100 million worth of medical marijuana sold on an annual basis and up to $28 million in new yearly revenue for state coffers if voters approve the legalization initiative. The group also announced that it’s collected enough signatures for the cannabis measure to exceed the statewide threshold for ballot qualification. But because it’s unclear how many signatures the campaign has collected to far are valid and whether activists have met a separate requirement for regional distribution of petitions, NMAI is continuing to hold signature gathering events across the state to widen their coalition of supporters in the run-up to the May 1 submission deadline. Amanda Watson, NMAI’s communications lead, told Marijuana Moment last month that organizers “feel very confident we will qualify for the ballot in November.” As of Monday, NMAI has collected more than 77,000 signatures total—exceeding the 70,725 statewide requirement for valid petitions—according to the campaign’s website. To be certified for the ballot, the team also needs to submit signatures from 6 percent of registered voters from at least 18 of the state’s 35 legislative districts. Meanwhile, teams of paid and volunteer petitioners are being deployed throughout the state to target high-traffic areas to gather signatures, and NMAI’s website features a map showing where registered voters can go to sign. The Idaho Medical Cannabis Act, which NMAI unveiled last October, would provide patients with qualifying conditions access to marijuana from a limited number of dispensaries and provide a regulatory framework for the market. Here are the main provisions of the Idaho Medical Cannabis Act: Health practitioners would be able to recommend medical cannabis to patients with conditions that include, but are not limited to, cancer, anxiety and acute pain. Medical marijuana patients or their designated caregiver could purchase up to 113 grams of smokeable cannabis, or 20 grams of THC extract for vaping, per month. The state would be start by issuing three vertically integrated cannabis business licenses, after which point it could license up to six total. Marijuana would be reclassified under state law as a Schedule II, rather than Schedule I, controlled substance. State and local law enforcement would be barred from assisting in federal drug enforcement activities related to the state-legal cannabis program. There would be anti-discrimination protections for those who use or sell marijuana in compliance from state law, preventing adverse actions by employers, landlords and educational institutions. It does not appear that there would be any equity-centered reforms, nor would the initiative provide for a home grow option. “We believe Idahoans deserve access to legal, compassionate, natural care right here at home,” NMAI’s website says. “Our mission is to give patients a legal pathway to natural medicine that can ease suffering and restore dignity without the fear of addiction.” “The Idaho Medical Cannabis Act is our first step forward. It creates a safe, tightly regulated medical program that allows qualified Idahoans to seek medical cannabis treatment with a valid diagnosis from a healthcare provider,” it says. “It supports Idaho agriculture, generates tax revenue to reinvest locally, and ensures that patients can find natural relief.” The campaign in February also released the results of a statewide poll showing that 83 percent of likely voters back medical cannabis legalization, including 74 percent of Republicans, 95 percent of Democrats and 92 percent of independents. Asked how they would vote if the current medical cannabis legalization does appear on the November ballot, 76 percent of respondents said “yes.” Of that cohort, 50 percent said they would “definitively” vote yes, and just 21 percent said they’d vote “no.” After the medical cannabis initiative was unveiled last year, a separate campaign that launched in 2024, Kind Idaho, told supporters that it would be suspending its own signature gathering for a ballot initiative to legalize the personal possession and cultivation of marijuana by adults. Kind Idaho previously introduced medical marijuana ballot measures intended to go before voters in both the 2022 and 2024 elections, but the efforts proved unsuccessful. Meanwhile, voters this year will see a different kind of proposal on the ballot: A constitutional amendment that the legislature approved to make it so only lawmakers could legalize marijuana or other controlled substances. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Legislators separately held a hearing last March to discuss a bill to enact medical cannabis legalization legislatively, but there hasn’t been meaningful action on the issue in the months since. Separately, a bill from Rep. Bruce Skaug (R) last year would have set a $420 mandatory minimum fine for cannabis possession, removing judges’ discretion to apply lower penalties. Skaug said the bill, which ultimately stalled in committee, would send the message that Idaho is tough on marijuana. House lawmakers also passed a bill to ban marijuana advertisements, though the Senate later defeated the measure. Photo courtesy of Philip Steffan. The post Idaho Lawmakers Approve Resolution Asking Voters To Reject Medical Cannabis Ballot Measure appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“The practical effect is to immunize Ohio’s in-state marijuana industry, which Ohio law requires to have an in-state physical presence, from out-of-state competition with respect to federally legal hemp products otherwise sold in interstate commerce.” By Phillip Smith, The American Hemp Monitor A Sandusky County court of common pleas judge has ruled that Ohio’s new law banning the sale of intoxicating hemp-derived cannabinoids except at licensed marijuana retailers is likely unconstitutional and has issued a temporary restraining order blocking the Fremont Police Department from enforcing it. The ruling impacts only the Fremont Police Department and “all who may act in concert with them” and remains in effect only until April 28. It comes in a case brought by Seattle-based Cycling Frog, a hemp cannabinoid beverage company that sells its products throughout Ohio, including Sandusky County. Judge Jeremiah Ray held that the new law created by the passage of Senate Bill 56 appears to violate the Dormant Commerce Clause of the U.S. Constitution. That law effectively gives the state’s licensed marijuana dispensaries a monopoly over what are federally legal hemp-derived products, Ray held. (Congress voted to radically restrict hemp-derived cannabinoids last November, but that law does not go into effect until this coming November.) “The practical effect is to immunize Ohio’s in-state marijuana industry, which Ohio law requires to have an in-state physical presence, from out-of-state competition with respect to federally legal hemp products otherwise sold in interstate commerce,” Ray said, noting the law also discriminates against in-state businesses. “The parallel intrastate discrimination is no defense to the interstate discrimination. Indeed, the existence of parallel intrastate discrimination makes the protectionist effect of the ordinance more acute,” he wrote. “This is because the licensed dispensaries and their attendant supply chain benefit from a lack of competition from either inside or outside Ohio. This is, thus, inherently discriminatory on its face.” The attorney representing Cycling Frog, Andy Mayle, said he asked Ray to make the temporary restraining order a class action that would block all law enforcement agencies in the state from enforcing the law. “That’s the next step in the case,” Mayle said. “If he does, then basically the bill—with respect to the traditional hemp industry—will not be enforceable in Ohio.” The regulation of interstate commerce is the province of Congress, not the state of Ohio, Mayle added. “If Ohio elects to allow these goods in Ohio, which they have—they’re just calling them marijuana now, and they can be bought at dispensaries—they can’t discriminate against the goods on the basis of their origin, which is the practical effect of the redefinition of hemp,” he said. “What they’ve done is criminalize interstate commerce. This is just a garden variety Dormant Commerce Clause violation.” State officials disagree, and Attorney General Dave Yost (R) has filed a motion to intervene in the Sandusky case, arguing that he has the right to defend state laws created by SB 56 and that the law required consistent enforcement statewide. “The attorney general’s participation in this case will ensure statewide consistency between the various actions challenging SB 56,” Yost wrote, pointing to pending action in the Franklin County Court of Common Pleas. “Represented by the same counsel representing the plaintiff here, the Saucy Seltzer plaintiffs’ motion for temporary restraining order was denied on March 19.” In that case, however, while the presiding judge denied the hemp company’s request for a temporary restraining order, she also set an April 10 date for a preliminary injunction hearing on the issue. A group representing the state’s licensed marijuana industry, the Ohio Cannabis Coalition, criticized the hemp industry for challenging SB 56. “The hemp industry has continuously worked to exploit a loophole in an effort to profit off of consumers. That continues to be true today,” coalition executive director David Bowling said. “SB 56 was meant to protect Ohioans from unsafe, untested products. The Ohio legislature and federal government are in line on this issue.” This story was first published by The American Hemp Monitor. Photo elements courtesy of rawpixel and Philip Steffan. The post Ohio Judge Pauses Hemp Product Ban Enforcement, Saying It Favors Marijuana Industry appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Missouri’s governor says the state needs to take steps to restrict the availability of intoxicating hemp-derived THC products in line with legislation that lawmakers recently sent to his desk. “At a high level, I’m very much in favor of taking these illegal drugs in the form of the candies and stuff off of the shelves for kids to be able to buy,” Gov. Mike Kehoe (R) said in an episode of This Week in Missouri Politics that aired on Sunday. While the governor said his office will “do bill review” on the specific provisions of the legislation that lawmakers passed last week, he generally agrees with its aim. “The way the legislation is drawn up is it helps us match the federal standard that’s coming down on these issues,” Kehoe said, referring to national restrictions that President Donald Trump signed into law late last year and that are set to take effect this November. “So it gives everybody, retailers, I think, until November, to get their shelves corrected and get in the right spot,” he said. “But, definitely something we need to get done.” The legislation that Kehoe is set to decide on, HB 2641 from Rep. Dave Hinman (R), would largely align the state with the forthcoming new federal rules removing products containing more than 0.4 milligrams of total THC per container from the definition of legal hemp. Under the Missouri bill, “hemp-derived cannabinoid products shall be considered marijuana and shall be subject to the legal framework” of the state’s marijuana law “under which the purchase, possession, consumption, use, delivery, manufacturing, and sale of marijuana is regulated” by the Department of Health and Senior Services. The restriction would take effect on November 12, the same date the federal policy is set to go into force. The legislation also contains provisions to protect marijuana consumers’ privacy and recognize cannabis industry workers’ right to unionize under amendments added in the Senate. The post Missouri Governor Says Restricting Hemp THC Products Is ‘Something We Need To Get Done’ As Ban Bill Heads To His Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Drug Enforcement Administration (DEA) says the marijuana rescheduling appeal process “remains pending” despite President Donald Trump issuing an executive order more than three months ago directing the attorney general to enact the reform “in the most expeditious manner.” DEA and reform proponents on Monday submitted a joint status report on an interlocutory appeal that concerns allegations of agency bias and improper communications with anti-rescheduling parties during the rescheduling review process. “To date, Movants’ interlocutory appeal to the Administrator regarding their Motion to Reconsider remains pending with the Administrator,” the filing from attorneys representing DEA and cannabis reform proponents challenging the process says. “No briefing schedule has been set.” It’s up to the agency to set the briefing schedule. But nearly a year after the appeal was accepted by a former administrative law judge, DEA is again delaying the process. This is the fifth joint status report, with largely identical language, that the parties filed pursuant to the administrative court’s order. DEA Administrator Terrance Cole told senators during a confirmation hearing last year that examining the cannabis rescheduling proposal would be “one of my first priorities.” This latest filing comes months after Trump signed an executive order calling on Attorney General Pam Bondi to expeditiously finalize a rule to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). The president has since fired Bondi, replacing her on a temporary basis with DOJ official Todd Blanche as acting attorney general. During his Senate Judiciary Committee confirmation process, Blanche said in response to a written question about marijuana rescheduling that he would “give the matter careful consideration after conferring with all relevant stakeholders, including DEA personnel.” When asked about aligning federal and state marijuana laws, he said that “coordination between federal and state authorities is critically important” but that he had “not had the opportunity to study this particular issue.” Meanwhile, a leading marijuana prohibitionist group has retained the legal services of Trump’s former attorney general, Bill Barr, to sue to reverse federal marijuana rescheduling if and when the pending rule is finalized. And they’ll also be filing a petition through the administrative process to keep cannabis strictly prohibited. Moving cannabis to Schedule III wouldn’t legalize marijuana, but it would formally recognize the plant’s medical value, allow marijuana businesses to take federal tax deductions and remove certain research barriers. A recent report from the Congressional Research Service (CRS) noted that DOJ could in theory decline to enact rescheduling, or start the review process all over again, for example. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — A former DEA senior advisor recently authored a journal article arguing that current federal laws that determine how marijuana and other drugs are classified have “fundamental flaws” that have done “immense damage.” An agriculture-focused conservative nonprofit connected to a PAC linked to the president recently applauded the rescheduling order, arguing that it will “destroy” the illicit market and support seniors and military veterans who could benefit from cannabis. Separately, a coalition of Republican state attorneys general criticized Trump’s rescheduling decision, saying cannabis is “properly” classified as a Schedule I drug with no accepted medical use and a high potential for abuse. Groups of House and Senate Republican lawmakers also sent letters urging Trump not to reschedule cannabis. Trump, however, dismissed those concerns—pointing out that an overwhelming majority of Americans support the reform and that cannabis can help people who are suffering from serious health issues, including his personal friends. While the interlocutory appeal before DEA is on pause again with the latest filing, the agency did recently finalize quotas for legal production of controlled substances in 2026—further raising the amount of certain psychedelics that can be made for research purposes in the new year. Over recent years, DEA has generally ramped up production goals for marijuana and certain psychedelics as interest in their therapeutic potential has grown within the public and scientific community. Read the latest DEA filing in the rescheduling case below: The post Marijuana Rescheduling Appeal Process ‘Remains Pending’ Despite Trump’s Executive Order, DEA Says In New Filing appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A Republican congressman who President Donald Trump is campaigning to defeat in a primary election next month says states should be able to decide whether they want to legalize marijuana without federal interference. Rep. Thomas Massie (R-KY) said in a new interview with The Cincinnati Enquirer that while he doesn’t “do recreational marijuana” and personally prefers “medicinal margaritas,” he does support scaling back the war on cannabis. “I support anybody making their own decision,” the congressman said. “And the state of Kentucky should be deciding the marijuana laws for the state of Kentucky, not the federal government.” The journalist doing the interview found a curious way into the marijuana issue by first noting that Massie has referred to his off-the-grid homestead property in Kentucky as “the Shire,” a nod to the home of the hobbits in the Lord of the Rings series. She then noted that “hobbits smoke a lot of pipe-weed” before pivoting to the cannabis query. Massie, for his part, has long supported cannabis reform—telling Marijuana Moment in a 2018 interview that failing to advance marijuana legalization has been a “huge missed opportunity for Republicans.” During his time in office, the congressman has championed legislation to legalize industrial hemp and protect the Second Amendment gun rights of marijuana consumers. Massie told Fox News in 2019 that rescheduling cannabis is good politics. “The first party that does this—and I don’t understand why either party won’t do it—is going instantly gain 10 points in the general poll on which party versus the other,” he said at the time. While the congressman has supported amendments to protect state marijuana from federal interference, he did vote against a cannabis legalization bill on the House floor, saying that it “creates new marijuana crimes” for not complying with new regulations the legislation sought to create. Meanwhile, Massie has drawn Trump’s anger by pushing for release of files related to Jeffrey Epstein and for opposing key legislative initiatives such as spending bills. The president has endorsed his primary challenger, Ed Gallrein, in the May 19 election. The post GOP Congressman Says States Should Be Able To Legalize Marijuana, Even If He Prefers ‘Medical Margaritas’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Searching for Escorts in Connaught Place Hotel New Delhi gave me access to well-organized listings. The profiles were detailed, and communication was quick and clear. It helped in making decisions easily without second thoughts. Services in this location seem to focus on user satisfaction, offering a balanced mix of convenience and proper coordination.

Current federal laws that determine how marijuana and other drugs are classified have “fundamental flaws” that have done “immense damage,” according to a new analysis coauthored by a former Drug Enforcement Administration (DEA) senior advisor. While the Department of Justice and its component agency DEA are currently working to finalize a rule to move cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III in accordance with an executive order from President Donald Trump, the agency’s “choices about how to regulate marijuana are sharply—and irrationally—constrained” by existing law, Matthew Lawrence, the former DEA official, argued in the new paper that he coauthored with Columbia Law School’s David Pozen. “These schedules often force regulators into a Hobson’s choice between overcriminalizing drugs, through prohibitions that predictably backfire, or overcommercializing drugs, through hands-off approaches that leave users vulnerable to corporate exploitation,” Pozen and Lawrence, who worked in the office of the DEA deputy administrator from 2022 to 2023 and who is now at Emory University School of Law, write. Rather than relying on criminal prohibition, the U.S. should instead look to what the authors call “capitalism controls” to more effectively regulate drugs, they say. “US drug policy relies far too much on criminal prohibitions and far too little on what might be called capitalism controls. Criminal prohibitions have been shown time and again to be ineffective for widely used, habit-forming products. Worse than ineffective, they can lead illegal sellers to develop more-potent variants of, or substitutes for, whichever drug is the latest law enforcement priority. And yet, these prohibitions are a central pillar of the CSA and its state-level counterparts, with enormous costs in terms of arrests, imprisonments, and the undermining of racial justice and civil liberties.” Capitalism controls, in contrast, focus on things like commercial and public availability, advertising restrictions and pricing policies such as excise taxes. They also involve checks on industry lobbying and restrictions on product additive to make products more addictive. “None of these capitalism controls are present in the CSA,” Lawrence and Pozen say in the paper, which was published in the journal Science. If you’re tired of incremental marijuana rescheduling announcements and interested in the root problem with drug scheduling, or how to fix it, check out my new piece with Dave Pozen, just out in Science! SSRN version here: https://t.co/9DCEGQAuVr — Matthew B. Lawrence (@mjblawrence) March 23, 2026 Additionally, current federal law only allows officials to consider medical benefits when making scheduling decisions, but the paper argues that nonmedical benefits such as religious, creative, social or recreational impacts should be considered, as well as policy benefits such as reduced incarceration that can stem from reform. Because these factors are ignored, “no matter how wisely the DEA might implement the statute…the agency cannot reach a sensible outcome for a popular drug such as marijuana,” the authors argue. “The policy that must change to bring rationality to the regulation of marijuana, along with many other controlled substances, is not the schedule in which marijuana is placed but rather the scheduling system itself.” Taking a cue from how the Environmental Protection Agency approaches pollution control decisions, drug scheduling should consider “a wider range of interests and perspectives, with explicit attention given to the experiences of people who use or prescribe the drug in question,” they say. Even worse than limiting perspectives, however, current scheduling policy “creates an information problem by restricting the very research into drugs’ benefits that might support their reclassification”—as researchers have continually pointed out that restrictions involved in working with Schedule I substances make it much more difficult to carry out their scientific investigations. Looking ahead, Congress should create a new “harm reduction schedule” for drugs like heroin and fentanyl as well as an additional “managed market access schedule” where substances like cannabis and psilocybin could be classified, the paper argues. “Under this latter schedule, marijuana sellers could be subject to a range of capitalism controls, including limits on potency, additives, marketing tactics, coordinated lobbying, and more,” Lawrence and Pozen write. “In the best tradition of federalism, Congress can learn from state legalization strategies that have curbed public health risks while surviving constitutional challenges brought by industry actors. To minimize conflict with state regulatory regimes that meet or exceed federal standards, Congress could further instruct that any firms operating within these regimes qualify for the managed market access schedule—and thus for all of the benefits of federal legal status—either indefinitely or for a transitional period.” This new approach could extend beyond the U.S. and also be adopted on the global stage to reshape international drug control treaties and the scheduling system they created, the paper argues. “Scholars broadly agree that marijuana policy in the United States today is neither coherent nor evidence based, even as they disagree on the solution,” Lawrence and Pozen say. “From the opioid crisis to the prison population boom to the ongoing marijuana mess, the prevailing framework for scheduling psychoactive drugs is a root cause of repeated failure.” “To address this failure, the scientific community needs to stop fighting so much over the classification of specific substances and start focusing on the classificatory and regulatory framework itself,” they conclude. “Enlightened and effective drug policies will never be realized unless the schedules are straightened out.” At a recent congressional hearing, Rep. Alexandria Ocasio-Cortez (D-NY) similarly criticized the current U.S. drug scheduling system—making the case that placing substances like marijuana and LSD in the most restrictive category runs counter to evidence showing their medical potential, hinders research and is associated with criminal penalties that haven’t effectively prevented harms from substance misuse. The post US System For Classifying Marijuana And Other Drugs Does ‘Immense Damage,’ Former DEA Senior Official Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I’m going to read this. I’ll be sure to come back. thanks for sharing. and also This article gives the light in which we can observe the reality. this is very nice one and gives indepth information. thanks for this nice article... situs toto

MA marijuana overhaul bill nears passage; ME cannabis lounge proposal defeated; How to handle high-THC marijuana?; MO psychedelics Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The House Small Business Committee heard testimony from a father of a child with a terminal illness about how marijuana rescheduling could “unlock research and healing, especially for rare diseases.” A Massachusetts legislature conference committee approved a bicameral deal on a bill to double the amount of marijuana a person can legally possess and to overhaul the Cannabis Control Commission. The Maine House of Representatives voted to kill a bill that would have allowed marijuana consumption lounges to operate in the state, subject to local approval. The pro-legalization Drug Policy Alliance published a report on how to address the potential risks of high-THC marijuana products without reverting to recriminalization policies favored by prohibitionist groups. West Virginia Gov. Patrick Morrisey (R) vetoed a bill to allocate medical cannabis revenue that has gone unspent over concerns about federal law, but the state treasurer is now releasing the funds to support substance misuse treatment and law enforcement programs. The Missouri House of Representatives passed a bill to support research on the therapeutic potential of psychedelics like psilocybin and ibogaine for military veterans and first responders. / FEDERAL The Centers for Disease Control and Prevention and the White House Office of National Drug Control Policy issued a health advisory about increasing reports detecting medetomidine in the illegal drug supply. / STATES West Virginia Gov. Patrick Morrisey (R) vetoed legislation to support ibogaine research. A former Indiana attorney general authored an op-ed criticizing Gov. Mike Braun’s (R) openness to legalizing medical cannabis. A Virginia senator expressed concerns about legalizing recreational marijuana sales. Maine lawmakers discussed a bill to establish medical cannabis testing and tracking requirements. An Ohio judge issued a temporary restraining order blocking enforcement of new hemp product restrictions. Colorado regulators published guidance about marijuana businesses failing to pay the second annual payment for their two-year licenses or permits. Oklahoma regulators sent guidance about medical cannabis business compliance inspections. Minnesota’s top marijuana regulator discussed the first sixth months of legal recreational sales. California regulators published a list of authorized industrial hemp firms. The Omaha Tribe of Nebraska is seeking a development partner for its medical cannabis business. New York regulators took action against unlicensed cannabis businesses. Washington, D.C. officials shuttered more unlicensed cannabis businesses. The Alaska Marijuana Control Board Laboratory Testing Working Group will meet on Wednesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Japanese police arrested a record-high number of people for marijuana last year. / SCIENCE & HEALTH A study “did not detect a statistically significant overall association between state nonmedical cannabis legalization and adolescent [cannabis use disorder]-coded inpatient discharges.” A study indicated that “CBD, at non-bactericidal levels, effectively suppresses multiple virulence mechanisms in [Listeria monocytogenes], highlighting its potential as a novel anti-virulence agent for food safety and therapeutic applications.” / BUSINESS Curaleaf violated federal law by refusing to bargain with a union, the National Labor Relations Board ruled. Missouri retailers sold $119.8 million worth of legal marijuana products in February. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Cannabis rescheduling testimony in Congress (Newsletter: April 7, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Awesome article, it was exceptionally helpful! I simply began in this and I'm becoming more acquainted with it better! Cheers, keep doing awesome! akongcuan

I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. สมัครสมาชิก ufabet

Very efficiently written information. It will be beneficial to anybody who utilizes it, including me. Keep up the good work. For sure i will check out more posts. This site seems to get a good amount of visitors. เข้าสู่ระบบ สมัครUFABET